Johns Hopkins Medicine researchers link Aplp1 and Lag3 proteins in spreading Parkinson's-related alpha-synuclein, identifying a potential cancer drug target for slowing progression.
Johns Hopkins Medicine researchers found that cell surface protein Aplp1 connects with Lag3, another cell surface receptor, in spreading harmful alpha-synuclein proteins linked to Parkinson's disease. Lag3 is a target of an FDA-approved cancer drug, suggesting potential for slowing Parkinson's progression by targeting Aplp1-Lag3 interaction. The researchers plan anti-Lag3 antibody trials in mice with Parkinson's and Alzheimer's diseases.
June 17, 2024
4 Articles